Business
NurExone Announces Completion of Securities for Debt Settlements
Calgary, Alberta--(Newsfile Corp. - November 8, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FS...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Announces Completion of Securities for Debt SettlementsCalgary, Alberta--(Newsfile Corp. - November 8, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or \"EnerSpar\") (the \"Company\" or \"NurExone\"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities for debt settlements, previously announced by the Company on September 1, 2022 and September 19, 2022. The Company agreed to settle debts in the aggregate amount of CAD$136,155.83 with the issuance of 170,195 common shares of the Company at a deemed price of CAD$0.80 per share (including the issuance of 117,033 by James (Jay) Richardson, a director of the Company). The Company also agreed to settle additional debts in the aggregate amount of CAD$75,000 with the issuance of 178,571 common shares of the Company at a deemed price of CAD$0.42 per share.The common shares issued will be subject to a four-month plus one-day hold period pursuant to the policies of the TSX Venture Exchange.About NurExone Biologic Inc.NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is, through its wholly-owned subsidiary, Nurexone Biologic Ltd., developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone intends to translate the treatment to humans, and the company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.For more information, please contact:Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: [email protected] investors:Investor [email protected]+1 905-347-5569DISCLAIMER AND READER ADVISORYNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has in any way passed upon the merits of the contents of this press release and neither of the foregoing entities accepts responsibility for the a...